Abstract
<jats:title>Abstract</jats:title><jats:p>The COVID-19 pandemic progresses unabated in many regions of the world. An effective antiviral against SARS-CoV-2 that could be administered orally for use following high-risk exposure would be of substantial benefit in controlling the COVID-19 pandemic. Herein, we show that MK-4482, an orally administered nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model. The inhibitory effect of MK-4482 on SARS-CoV-2 replication is observed in animals when the drug is administered either beginning 12 h before or 12 h following infection in a high-risk exposure model. These data support the potential utility of MK-4482 to control SARS-CoV-2 infection in humans following high-risk exposure as well as for treatment of COVID-19 patients.</jats:p>
Original language | English |
---|---|
Number of pages | 0 |
Journal | Nature Communications |
Volume | 12 |
Issue number | 1 |
Early online date | 16 Apr 2021 |
DOIs | |
Publication status | Published - 16 Apr 2021 |